In May 2016, the U.S. Food and Drug Administration issued a drug safety communication for type 2 diabetes patients taking Invokana™ or Invokamet™. The FDA’s warning came after two large clinical trials found that taking these medications nearly doubled the risk of foot, leg and toe amputations for type 2 diabetics compared with non-users. Now, type 2 diabetes patients suffering from lower limb amputations are suing the drug’s manufacturer, Johnson & Johnson, to get the justice and compensation they deserve.
Time is limited! Fill out the form on this page to see if you qualify.
An advocate or attorney will contact you within minutes for your free consultation.
No fees unless you are awarded compensation!
Invokana (canagliflozin) belongs to a newer class of drug called SGLT2 inhibitors which are commonly prescribed to manage blood sugar levels in type 2 diabetics. Taking SGLT2 inhibitors helps eliminate excess blood sugar by excreting it through urine.
Other popular SGLT2 inhibitor medications include:
In addition to warning about increased foot, leg and toe amputation risks, the FDA issued a May 2015 drug safety communication about the increased risk of developing ketoacidosis while taking SGLT2 inhibitors. Also known as diabetic acidosis, the condition occurs from excessive ketones in the patient’s bloodstream, which can be fatal. Other life-threatening Invokana complications include kidney damage, heart attack, stroke and renal failure.
